Manulife: The Market Punished The Wrong Q1

Manulife stock sold off almost 6% after Q1 2026 earnings on a single line item, while its Asia core earnings grew 22% and NBV 15%. The residual income valuation model anchored on Damodaran's industry beta puts intrinsic value at C$76 vs. C$52; on per-name beta, roughly fair. MFC's reported P/B of 2.0x ignores C$25.6B of net CSM. On adjusted book value, MFC trades at 1.3x.